Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study

Table 2 Biochemical changes during the seven-day observational period

	Day 0	Day 1	Day 2	Day 3	Day 7
25(OH)D (ng/ml)
Placebo group	14.1	15.3*	15.0*	14.5*	13.7*
Vitamin D group	13.1	20.5*^§	33.1*^§	35.1*^§	38.2*^§
1,25(OH)₂D (pmol/l)
Placebo group	50.6	36.3*	36.6	47.1	67.0
Vitamin D group	68.6	89.5*^§	175.2*^§	170.8*^§	114.2
PTH (pg/ml)
Placebo group	91.3	72.0	79.0	75.7	71.7
Vitamin D group	73.7	65.1	77.3	100.4	52.0
Ionized serum calcium (mmol/l)
Placebo group	1.03	^-	-	1.05	1.14^§
Vitamin D group	1.09	^-	-	1.11	1.14^§
Total serum calcium (mmol/l)
Placebo group	2.03	2.02	1.98	2.02	2.13^§
Vitamin D group	2.05	2.05	2.09	2.12	2.20^§
Serum phosphorus (mmol/l)
Placebo group	1.57*	1.34	1.49*	1.51*	1.22
Vitamin D group	1.01*	1.20	1.08*	1.07*	1.17
Triglycerides (mg/dl)
Placebo group	111	126	-	-	116
Vitamin D group	180	175	-	-	178
NTproBNP (pg/ml)
Placebo group	2100	-	-	-	2120
Vitamin D group	3089	-	-	-	3117
Urinary calcium/creatinine ratio (mmol/mmol)
Placebo group	0.38	0.24	0.14	0.15	0.41
Vitamin D group	0.38	0.19	0.27	0.28	0.27

1,25(OH)₂D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D, NTproBNP, N-terminal prohormone brain natriuretic peptide; PTH, parathyroid hormone.
§, P < 0.05 for intra-group comparisons (calculated in relation to baseline values) and *, P < 0.05 for between-group comparisons.

ISSN: 1364-8535